/生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ 美丽健康 | 自然堂、极地酵母喜默因® 原料是化妆品行业的"美丽之芯"，是产品竞争力的根本。 【SynBioCon】 获 悉， 8月27日， 自然堂集团 举办 自然堂第三极生物发酵原料工厂 （以下简称"自然堂发酵工厂"）启用仪式，这座全面应用 第五 代智能生物发酵技术 的"硬核"工厂 正式宣告投产，标志着自然堂在自主研发核心功效原料的征程上迈出关键一步。 年产1000吨，第五代发酵科技超级工厂投产 据悉，区别于前四代技术，自然堂的第五代发酵技术，融合了 微生物学、合成生物学、数据科学与AI，推动菌种构造、验证及工业化效率升级 ，尤其 在研发端和生产端深度融合人工智能、计算信息学与生物信息学等交叉学科，通过 高通量实验筛选最优菌株与工艺组合 ，不仅将原料品质的稳定性与 纯度提升至新高度，更实现了功效成分的精准富集。 工厂拥有两条平行生产线， 单批次即可实现20吨的高效产能，年产能达到1000吨 。相比传统代加工的3-5吨/批，该技术支撑下的发酵原料批产量跃 升至 10-15吨/批 ，实现了约 5倍 的大幅提升。 并 ...

Core Viewpoint - The collaboration among Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical aims to establish a limited liability partnership, Setouchi Ethylene LLP, focusing on carbon reduction technologies and capacity optimization in ethylene production facilities in western Japan, with a goal of achieving a green transition by 2030 [2][5]. Group 1: Ethylene Production and Carbon Emissions - Ethylene is one of the largest chemical products globally, with its production process accounting for 1.8% of global industrial emissions, primarily due to high-temperature energy consumption in steam cracking furnaces [5]. - Japan, as the third-largest ethylene producer, has an annual capacity of approximately 10 million tons, but its carbon intensity is 20%-30% higher than that of Europe and the U.S. [5]. - The Japanese Ministry of Economy, Trade and Industry (METI) plans to achieve a 40% reduction in emissions from the chemical industry by 2030, making the stability, greening, and efficiency optimization of ethylene production crucial for the development of downstream engineering plastics [5]. Group 2: Strategies for Green Transition - The three companies have been discussing specific measures to promote carbon neutrality in ethylene production facilities since last year, focusing on transitioning raw materials from traditional petroleum resources to biomass-based materials and introducing low-carbon fuels [6]. - They plan to optimize production frameworks, including potential capacity reductions for more efficient resource utilization, and have agreed that forming the LLP is the best way to deepen cooperation and accelerate their goals [6]. - Asahi Kasei has developed a "lignin cracking technology" that can convert paper waste and other biomass into ethylene feedstock, which can replace some petroleum-based raw materials. Pilot data shows that with a biomass ratio of 20%, carbon emissions can be reduced by 35%, and costs are 15% lower than traditional bioethanol routes [6]. Group 3: Differences Between Bio-based Olefins and Traditional Ethylene - Bio-based ethylene opens a new pathway for ethylene production, sourced from renewable biomass resources such as agricultural and forestry waste, through a series of biological and chemical conversion processes [7]. - The carbon emissions from bio-based ethylene production are significantly lower, with CO2 emissions ranging from 0.8 to 1.2 kg CO2 per kg of product, representing a 60% reduction compared to petrochemical routes [7]. - However, challenges remain in terms of cost competitiveness, with raw material costs accounting for 60%-70% of total costs, and higher energy consumption compared to petrochemical processes [7]. Group 4: Industry Movements and Innovations - Major companies like Braskem, BASF, and New Energy Blue are pursuing bio-based ethylene as a key focus area in the context of low-carbon sustainability [7]. - Braskem, the sixth-largest petrochemical company globally, has been producing bio-based polyethylene since 2010 and is expanding its bio-based ethylene production capacity in Brazil [8]. - In China, Sinopec has made significant strides in bio-based polyethylene, successfully launching its first bio-based product in September 2024, with an initial production of 2,500 tons [10].

主要起草单位包括 中石化(大连)石油化工研究 院有限公司、武汉睿嘉康生物科技有限公司、山东大学、中国科学院天津工业生物技术研究所、国投先进生 物质燃料(海伦)有限公司、北京首钢朗泽科技股份有限公 司、南京工业大学、山东龙力生物科技股份有限公司、南阳师范学院、通标中恒标准化技术研究 院(北京)有限公司 。 | 标准详细信息 | | | --- | --- | | 标准状态 | 现行 | | 标准编号 | T/CITS 506-2025 | | 中文标题 | 生物燃料乙醇 | | 英文标题 | Biofuel ethanol | | 国际标准分类号 | 75.160.01 燃料综合 | | 中国标准分类号 | | | 国民经济分类 | C254 生物质燃料加工 | | 发布日期 | 2025年08月05日 | | 实施日期 | 2025年08月05日 | | 起草人 | 张全、廖莎、李澜鹏、高慧鹏、李晓姝、杨世辉、李雪芝、田朝光、李金根、李春玲、杜长雷、岳美琪,王风、杨永富、何桥宁、王 | | | 霞、陈勇、武国庆、苗春雨、阎金龙、肖林、柯涛、赵建、刘岩、吴永利、汪贤峰、时俊伟、王艳杰、徐敬铭、包瑾、程胜楠。 | ...

SynBio团队 | 郑裕国院士团队汤晓玲、柳志强 L -蛋氨酸作为人体必需氨基酸，在饲料、医药、食品等领域具有不可替代的作用，其高效生物合成一直是生物技术领域的研究热点。课题组前期成 功建立起发酵-酶法合成 L-蛋氨酸 的技术路线，通过高效细胞工厂构建，发酵生产前体氧琥珀酰L-高丝氨酸（OSH），耦联O -琥珀酰- L -高丝 氨酸巯基转移酶（MetZ），实现L-蛋氨酸的合成。 但是，关键酶在高浓度底物 甲硫醇钠 环境下稳定性差，且蛋白质工程领域长期存在的"活性-稳定性权衡"问题，进一步导致其适应性改造困难。为 突破这一困境，研究团队创新性提出 "动态网络刚性化-局部柔性调控" 策略，结合共识序列分析与结构导向设计，精准锚定突变热点，实现酶活与 稳定性的协同提升。 【SynBioCon】 获 悉，近日， 郑裕国院士团队汤晓玲、柳志强教授 在 AIChE Journal 期刊上发表了题为《Structure-based engineering of O-succinyl-L-homoserine mercaptotransferase with improved substrate tolerance 》 的 ...

Core Viewpoint - The company Jia Bi You announced the termination of its acquisition of 63.21% equity in Ou Yi Biological after nearly 10 months of planning, citing changes in the external market environment as the reason for this cautious decision [2][6]. Summary by Sections Termination Reasons - Jia Bi You's latest announcement indicated that the termination of the acquisition was due to the failure to reach an agreement on core transaction terms, and the company has withdrawn its application documents [4][6]. Background of the Acquisition - Since October 29 of the previous year, Jia Bi You had been planning a major asset restructuring, initially aiming to acquire 65% of Ou Yi Biological's equity. This was later adjusted to 63.21% and involved a reduction in the number of transaction parties from 14 to 13 [7][8]. - The adjusted proposal included issuing 29.77 million shares at a price of 19.29 yuan per share, totaling a transaction price of 830.6 million yuan, which would have resulted in a significant goodwill addition of 721 million yuan, accounting for 43.3% of total assets and 47.21% of net assets as of September 30, 2024 [7][8]. Financial Performance - In the first half of the year, Jia Bi You reported a revenue of 307 million yuan, representing a year-on-year increase of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a growth of 59.01% [8].

Core Viewpoint - The establishment of the Ordos Synthetic Biology Technology Co., Ltd. marks a significant step in the synthetic biology sector in Inner Mongolia, aiming to create a leading domestic and globally competitive synthetic biology industry base through collaboration between Hangzhou Enhe Biotechnology Co., Ltd. and Ordos Electric Metallurgy Group [2][4]. Group 1: Project Development - The first synthetic biology project in Ordos, with an investment of 230 million yuan, aims to produce 4,000 tons of bio-based calcium propionate annually after the completion of the first phase [4]. - The project focuses on "efficient, green, and low-carbon" industrial biological manufacturing technology, transitioning from "laboratory research and development to large-scale production" [4]. - Upon completion, the project will become the largest producer of clean label products globally, securing a significant position in the international market [4]. Group 2: Strategic Collaborations - In May, Enhe Biotechnology signed a strategic cooperation agreement with Proya Cosmetics, marking Proya's first collaboration with a synthetic biology company to integrate synthetic biology, artificial intelligence, and bio-manufacturing technologies [5]. - The collaboration aims to innovate functional raw materials, develop medical beauty materials, and construct a green intelligent manufacturing system [5]. - In July, Hefei Yien Biotechnology Co., Ltd. was established with a registered capital of 10 million yuan, focusing on the manufacturing and research of bio-based materials, co-owned by Yili Group and Enhe Biotechnology [6].

Core Viewpoint - Despite facing overall performance pressure in the first half of 2025, Huaxi Biological's strategic adjustments have begun to yield results, indicating a potential turning point in profitability [2][3]. Financial Performance - In the first half of 2025, Huaxi Biological achieved operating revenue of 2.261 billion yuan, with a net profit attributable to shareholders of 221 million yuan, and a net profit excluding non-recurring gains and losses of 174 million yuan. The overall performance did not show growth [2]. - In Q2 2025, the company reported operating revenue of 1.183 billion yuan, a year-on-year decline of 18.44%. However, the net profit attributable to shareholders increased by 20.89% to 119 million yuan, marking the first year-on-year and quarter-on-quarter increase in net profit margin since Q1 2024 [2]. Strategic Transformation - The return of the General Manager to the front line has driven significant changes, shifting the company's strategy from "scale expansion" to a "benefit-oriented development model" centered on scientific research and innovation [3]. - Huaxi Biological aims to continue focusing on technological innovation to expand the application of synthetic biology and optimize its business structure for high-quality development [3]. R&D Investment - R&D expenses increased by 15.25%, focusing on three key areas: synthetic biology technology, industrialization of recombinant collagen, and microecological preparations, with a 30% improvement in strain modification efficiency [4]. - The company is actively developing new bioactive substances using cutting-edge synthetic biology technologies and has initiated 34 skin science innovation R&D projects and 17 nutrition science innovation R&D projects during the reporting period [4]. Industrial Application and Future Growth - Huaxi Biological is applying its leading synthetic biology manufacturing capabilities across three major sectors, establishing a complete R&D chain from basic research to technology transfer and industrial application [6]. - The company has completed process validation for its sterile HA production line and is advancing the national synthetic biology technology innovation center in Tianjin, aiming to overcome the "scaling up" bottleneck in biomanufacturing [6]. - The establishment of Huaxi Tang'an Biotechnology Co., Ltd. is noteworthy, as it utilizes synthetic biology technology for the precise synthesis of heparin polysaccharides, positioning the company to transition the heparin industry from "animal resource dependence" to "green biomanufacturing" [6].

Core Viewpoint - The collaboration between Inner Mongolia and Anhui Fengyuan Group aims to establish a green zero-carbon bio-manufacturing industrial base, aligning with national carbon neutrality goals and enhancing regional competitiveness in green manufacturing and bio-economy [2][4]. Group 1: Project Overview - The total investment for the Fengyuan (Northern) green zero-carbon bio-manufacturing industrial base project is 15.5 billion yuan, covering amino acid products, bio-materials, and bio-energy sectors [2]. - Upon full operation, the project is expected to generate annual sales revenue of approximately 26 billion yuan, tax revenue of about 3 billion yuan, and create around 3,500 jobs [2]. Group 2: Technological Innovations - Fengyuan Group has developed first and second-generation bio-manufacturing technologies using starch sugar and straw for sugar production, respectively [4]. - The company has established four major innovative technology platforms, including: 1. Technology for producing plant-based humic acid from agricultural and forestry waste [4]. 2. Three bio-based material platform technologies (PLA, bio-based polyurethane, bio-based polycarbonate) [4]. 3. Three bio-energy manufacturing technologies (cellulosic ethanol, biodiesel, bio-jet fuel) [4]. 4. Downstream application technologies for bio-based materials, including bio-fibers, bio-plastics, and bio-based construction materials [4]. Group 3: Strategic Importance - This project is a key part of Tongliao City's efforts to implement the autonomous region's strategy for high-quality development of emerging industries and modern industrial systems [4]. - The collaboration is expected to significantly enhance the competitiveness of Kailu County in the green manufacturing and bio-economy sectors, positioning it as an important growth pole for high-quality development in eastern Inner Mongolia [4].

Core Viewpoint - The financial performance of Chuaning Bio for the first half of 2025 shows significant declines in revenue and net profit, indicating challenges in the current market environment [2][3]. Financial Performance Summary - The company reported a revenue of 2.35 billion yuan, a decrease of 26.50% compared to the same period last year [3]. - Net profit attributable to shareholders was 455 million yuan, down 40.64% year-on-year [3]. - The net profit after deducting non-recurring gains and losses was 456 million yuan, reflecting a 40.38% decline [3]. - Basic earnings per share were 0.20 yuan, a decrease of 41.18% from the previous year [3]. - Cash flow from operating activities decreased by 49.32%, amounting to 391 million yuan [3]. - Total assets at the end of the reporting period were 10.16 billion yuan, down 3.74% from the previous year [3]. Strategic Focus and Future Directions - The company plans to enhance its core competitiveness through four strategic directions: 1. Reforming traditional antibiotic intermediates and Q10 through synthetic biology, utilizing gene editing and metabolic engineering to improve product efficacy and reduce production costs [4]. 2. Enhancing and cost-reducing existing products like red myrtle alcohol and squalene through optimization of strains and fermentation processes [4]. 3. Efficient biological utilization of C1/C2 resources, focusing on sustainable production of single-cell proteins and specialty chemicals [4]. 4. Developing larger-scale amino acids and vitamins [5]. Main Business and Product Overview - Chuaning Bio operates in the pharmaceutical manufacturing sector, focusing on "biological fermentation" and "synthetic biology" as dual driving strategies [5]. - The company has invested over 8 billion yuan in its fermentation projects, with a total production capacity of approximately 16,000 tons per year [6]. - Key products include thiocyanate erythromycin, cephalosporin intermediates, penicillin intermediates, and coenzyme Q10 [6]. - The synthetic biology project, with an investment of 1 billion yuan, has multiple products in production, making the company one of the few in the industry to complete the entire process from selection to large-scale production [6].

Core Viewpoint - Baoyi Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, attracting significant capital investment through multiple financing rounds totaling over 1 billion RMB since its establishment [2][5]. Financing Situation - Baoyi Pharmaceutical has completed several financing rounds, including 319 million RMB in A round (February 2021), 585 million RMB in B round (August 2022), and 426 million RMB in C round (July 2024) along with 45 million RMB in C+ round (December 2024) [2][3]. - The post-investment valuation reached 4.871 billion RMB after the latest financing rounds, with a share cost of 16.91 RMB [2][3]. Business Model and Strategy - The company focuses on developing recombinant biopharmaceuticals using synthetic biology technology, aiming to replace traditional biochemical extraction products and upgrade existing treatment methods [5][6]. - Baoyi Pharmaceutical's strategy aims to mitigate risks associated with traditional extraction methods, such as viral contamination and supply instability, while producing higher purity and more effective drugs at controlled costs [6]. Financial Performance - The company reported revenues of 6.93 million RMB in 2023, 6.16 million RMB in 2024, and 41.99 million RMB in the first half of 2025, with losses of approximately 160 million RMB, 364 million RMB, and 183 million RMB respectively during the same periods [6][7]. - R&D expenditures were significant, with 132.5 million RMB in 2023, 250.7 million RMB in 2024, and 111 million RMB in the first half of 2025, indicating a focus on expanding its product pipeline [6][7]. Product Pipeline - Baoyi Pharmaceutical has seven clinical-stage candidates and five preclinical assets, with three core products (KJ017, KJ103, SJ02) protected by comprehensive intellectual property rights [8][9]. - KJ017, a highly glycosylated recombinant hyaluronidase, has completed Phase III clinical trials in China and is set to submit a New Drug Application (NDA) in 2024 [8][9]. - KJ103 targets autoimmune diseases and has received approval for Phase II clinical trials in China, while SJ02 is expected to be commercialized by the end of 2025 [9]. Market Potential - The total clinical market size for the four therapeutic areas Baoyi Pharmaceutical is targeting is projected to exceed 50 billion RMB by 2033 [7].